Posted on: Tuesday, 13 May 2008, 15:00 CDT Meridian Bioscience, Inc. Cincinnati, Ohio (NASDAQ: VIVO) today announced it has executed a letter of intent to acquire a line of infectious disease recombinant proteins and cardiac antigens from Vybion, Inc. The purchase price includes cash and future...
[read full story]